We present the Clinical Trial results of the first Spanish intragastric balloon manufactured: the Stella® balloon (SwanMedical, Barcelona). As a peculiarity, it has a double lumen in the introducer system. The first one is intended for the passage of a guidewire to insert the balloon quickly and safely, which also requires prior gastroscopy.
View Article and Find Full Text PDFIntroduction: Intragastric balloon (IGB) is a minimally invasive and reversible option for obesity treatment. There is a worldwide growing number of different IGB models. The efficacy and safety profile for each model must be demonstrated.
View Article and Find Full Text PDFGastroenterol Hepatol
October 2024
Obesity is a multifactorial, chronic, progressive and recurrent disease considered a public health issue worldwide and an important determinant of disability and death. In Spain, its current prevalence in the adult population is about 24% and an estimated prevalence in 2035 of 37%. Obesity increases the probability of several diseases linked to higher mortality such as diabetes, cardiovascular disease, hyperlipidemia, arterial hypertension, non-alcoholic fatty liver disease, several types of cancer, or obstructive sleep apnea.
View Article and Find Full Text PDFBackground: Endoscopic sleeve gastroplasty (ESG) is an effective medium-term procedure for obesity treatment. There are no consistent studies confirming persistence of maintained gastric tubular configuration. We determined sleeve duration, gastric reduction degree, and suture persistence at 12-month follow-up.
View Article and Find Full Text PDFRev Esp Enferm Dig
December 2017
Dear Editor, We would like to clarify certain points in the article by C. Dolz et al. entitled "Informed consent in digestive endoscopy - Patient information, endoscopist protection", more specifically regarding the section "Obesity treatments".
View Article and Find Full Text PDF